1.
Lavanchy D: Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection : the official publication of the European Society
of Clinical Microbiology and Infectious Diseases 2011, 17(2):107-115.
2.
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA: A sustained virologic response reduces risk of all-cause mortality in patients with
hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal
of the American Gastroenterological Association 2011, 9(6):509-516 e501.
3.
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen
BE, Schalm SW, Janssen HL: Sustained virologic response and clinical outcomes in patients with chronic hepatitis
C and advanced fibrosis. Annals of internal medicine 2007, 147(10):677-684.
4.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z,
Foster GR, Horban A et al: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364(25):2417-2428.
5.
Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM,
Reddy KR, Goodman ZD, Boparai N et al: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364(13):1195-1206.
6.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer
H, Berg T, Yoshida EM et al: ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370(21):1973-1982.
7.
Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein
DE, Younes Z, Reindollar RW et al: Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving
ombitasvir/paritaprevir/r and dasabuvir for 12weeks. Journal of hepatology 2016, 64(2):301-307.
8.
Martin LM, Leff M, Calonge N, Garrett C, Nelson DE: Validation of self-reported chronic conditions and health services in a managed care
population. Am J Prev Med 2000, 18(3):215-218.
9.
Idler EL, Angel RJ: Self-rated health and mortality in the NHANES-I Epidemiologic Follow-up Study. American journal of public health 1990, 80(4):446-452.
10.
Ferraro KF, Wilkinson LR: Alternative Measures of Self-Rated Health for Predicting Mortality Among Older People:
Is Past or Future Orientation More Important? Gerontologist 2015, 55(5):836-844.
11.
Canini L, DebRoy S, Marino Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P,
Cotler SJ, Forns X et al: Severity of liver disease affects HCV kinetics in patients treated with intravenous
silibinin monotherapy. Antivir Ther 2015, 20(2):149-155.
12.
Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski
T, Weiss P, Cohen-Ezra O et al: HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and
in direct-acting antiviral treatment failure patients. Antivir Ther 2017, 22(5):431-441.
13.
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar
H, Xiong J, Pilot-Matias T et al: Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370(17):1594-1603.
14.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai
N, Nyberg A et al: ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370(21):1983-1992.
15.
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS,
Wedemeyer H, Tam E, Desmond P et al: Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370(17):1604-1614.
16.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Mullhaupt B, Horsmans
Y, Weiland O, Reesink HW et al: ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic
response with or without ribavirin in treatment-experienced patients with HCV genotype
1b infection. Gastroenterology 2014, 147(2):359-365 e351.
17.
Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horvath G, Jancsik V, Lengyel G, Makkai
E, Par A, Peter Z et al: Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected
patients who failed previous protease inhibitor therapy. Clin Exp Hepatol 2018, 4(2):83-90.
18.
European Association for the Study of the Liver. Electronic address eee, European
Association for the Study of the L: EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018.
19.
Saab S, Mehta D, Hudgens S, Grunow N, Bao Y, Pinsky B: Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related
quality of life for patients with hepatitis C. Liver international : official journal of the International Association for the Study
of the Liver 2018.
20.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R,
Gitlin N, Herring R et al: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370(16):1483-1493.
21.
Reddy KR, Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin
P, Welzel TM, Hyland R et al: Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection
and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015, 62(1):79-86.
22.
Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, Tran A,
Larrey DG, Ratziu V, Alric L et al: Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype
1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a
randomised, double-blind, phase 2 trial (SIRIUS). The Lancet Infectious diseases 2015, 15(4):397-404.
23.
Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia
A, Lai CL, Chan HL et al: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015, 373(27):2599-2607.
24.
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard
DM, Han L, Doehle B et al: Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients
With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Annals of internal medicine 2015, 163(11):809-817.
25.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourliere M,
Ruane PJ, Wedemeyer H et al: Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018, 378(4):354-369.
26.
Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T,
Hinrichsen H, Rincon D et al: Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or
6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label,
multicentre phase 3 trial. The Lancet Infectious diseases 2017, 17(10):1062-1068.
27.
Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon
SC, Flamm SL, Fried MW, Bernstein DE et al: Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection
and prior direct-acting antiviral treatment. Hepatology 2017, 66(2):389-397.
28.
American Association for the Study of Liver Diseases IDSoA: HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. wwwHCVGuidanceorg 2017.
29.
Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling
JM, Tran TT, Pianko S et al: Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med 2017, 376(22):2134-2146.